Apogee Therapeutics, Inc.
APGE
Classement en actions
#2365
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Prix de l'action
$135.07
Dernière synchronisation: 2026-09-04
Capitalisation boursière
$8.36B
Changement (1 jour)
0.00%
Changement (1 an)
137.21%
Pays
US
Échange Apogee Therapeutics, Inc. (APGE)
Catégorie
Healthcare
Ratio P/S pour Apogee Therapeutics, Inc. (APGE)
Ratio P/S au October 2026 TTM : 0.00
Selon les derniers rapports financiers et le cours de l'action de Apogee Therapeutics, Inc., le ratio cours/ventes actuel (TTM) est 0.00. À la fin de 2023, le ratio P/S était de 0.00.
Historique du ratio P/S pour Apogee Therapeutics, Inc. de 2022 à 2026
Ratio P/S à la fin de chaque année
| Année | Ratio P/S | Changez |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
Ratio P/S pour des entreprises similaires ou concurrentes
| Entreprise | Ratio P/S | Différence de Ratio P/S | Pays |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
